[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prostate-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prostate-cancers":389},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,58,82,112,157,190,226,268,291,326,362],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053420",false,"NCT06970275","To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","A Multicentric, Observational, Post-marketing, Registry Study to Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.","PETRiS","Inclusion Criteria :\n\nAll patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.\n\nPatients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.\n\nExclusion Criteria:\n\n* Under the age of 18 years at the time of resective surgery.\n* Women who are pregnant or breastfeeding.","ALL","18 Years",{"count":19,"type":20},850,"ESTIMATED","OBSERVATIONAL","This registry study aims to evaluate the effectiveness and clinical impact of specimen PET-CT imaging by analyzing the correlation between specimen PET-CT images, intraoperative interpretations, and histopathological findings. Additionally, it assesses how these imaging insights influence clinical decision-making and long-term patient outcomes. Through this comprehensive analysis in a real-world setting, the study seeks to generate valuable insights that can enhance specimen evaluation processes and ultimately improve patient care.",[24,25,26,27],"Prostate Cancers","Breast Cancer","Head and Neck Cancer","Cancer",[29,30,31,32],"PET-CT","Registry","Imaging","cancer","RECRUITING","2026-07-10",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2025-11-19",{"date":41,"type":20},"2031-01-15",{"name":43,"class":44},"XEOS Medical","INDUSTRY",2,{"id":47,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":49,"keywords":50,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":54,"completionDateStruct":55,"leadSponsor":56,"locationsCount":57},"100590658",{"count":19,"type":20},[24,25,26,27],[29,30,31,32],"2026-06-22",{"date":53,"type":37},"2026-06-25",{"date":39,"type":37},{"date":41,"type":20},{"name":43,"class":44},1,{"id":59,"slug":4,"hasResults":10,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":4,"eligibilityCriteria":63,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":64,"targetDuration":4,"studyType":66,"phases":67,"briefSummary":69,"conditions":70,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":57},"100567988","NCT06675357","Using FAPI PET\u002FMRI to Evaluate Prostate Cancer","Novel FAP-targeted Approach to Imaging Patients With or High-risk for Metastatic Prostate Cancer","Inclusion Criteria:\n\n* Age 18 years or older\n* Able and willing to provide informed consent\n* Known diagnosis of prostate cancer\n* Scheduled for or recently performed (within 4 weeks) standard-of-care PSMA PET\n* Optional: Scheduled for SOC biopsy of an established or suspected non-osseous, non-nodal metastases.\n* Willing and able to undergo PET\u002FMRI as part of this research\n\nExclusion Criteria:\n\n* Unable or unwilling to provide informed consent\n* Contraindication(s) to or inability to undergo PET\u002FMRI\n* Participants for whom PET\u002FMRI will delay timely delivery of treatment\n* Participants requiring intravenous (IV) conscious sedation for imaging care; those requiring mild, oral anxiolytics for the clinical MRI will be allowed to participate as long as the following criteria are met:\n* Have their own prescription for the medication\n* The informed consent process is conducted prior to the self-administration of this medication\n* Come to the research visit with a driver",{"count":65,"type":20},30,"INTERVENTIONAL",[68],"PHASE2","The goal of this clinical trial is to gain more information about how FAPI (fibroblast activation protein inhibitor) binds to certain type of cells in the tumor tissue. The main question it aims to answer is how this information can be used to better diagnose and track prostate cancer.\n\nParticipants will undergo two PET\u002FMRI scans during two research visits, each of which may last up to 2.5 hours.",[71,24],"Prostate Cancer Metastatic Disease","2026-06-09",{"date":74,"type":37},"2026-06-10",{"date":76,"type":37},"2026-02-27",{"date":78,"type":20},"2027-01",{"name":80,"class":81},"University of Wisconsin, Madison","OTHER",{"id":83,"slug":4,"hasResults":10,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":89,"targetDuration":4,"studyType":66,"phases":91,"briefSummary":93,"conditions":94,"keywords":100,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":111},"100587260","NCT06926075","Early Phase Study of KESONOTIDE™in Participants With Solid Tumours","An Adaptive Phase I\u002FII Study of KESONOTIDE™, a Novel hGIIA-vimentin Inhibitor, in Participants With Solid Tumours","ADVICE","Inclusion Criteria:\n\n* Male or female adults (defined as ≥ 18 years of age or acceptable age according to local regulations at the time of voluntarily signing of informed consent).\n* Has an ECOG performance status score of 0 or 1.\n* Has a life expectancy of \\> 12 weeks in the opinion of the investigator.\n* Measurable or evaluable disease by CT\u002FMRI according to RECIST v1.1, except for prostate and breast cancer (bone only metastases are acceptable) and glioma.\n* Histologically or cytologically confirmed locally advanced\u002Fmetastatic solid cancers.\n* Has adequate organ function within 7 days prior to Day 1 of Cycle 1, defined as below:\n* Laboratory Value\n* Hematology\n* Platelet count \\> 100 x 109\u002FL\n* Hb \\> 9.0 g\u002FdL\n* ANC \\> 1.5 x 109\u002FL\n* Renal Function\n* Creatinine \\\u003C 1.5 x ULN\n* Hepatic Function\n* AST and ALT \\\u003C 3 x ULN for the reference laboratory or \\\u003C 5 x ULN in the presence of liver metastases\n* Total bilirubin ≤ 1.5 x ULN\n* Serum albumin ≥ 2.5 g\u002FdL\n* INR\u002FPT and APTT ≤ 1.5 x ULN\n* Male and female participants of reproductive\u002Fchildbearing potential must agree to use adequate contraceptive methods (e.g., double barrier or intrauterine contraceptive) for at least 90 days during the study and after the last dose of study drug.\n* Male participants must not freeze or donate sperm starting at screening and throughout the study period, and at least 90 days after the final study drug administration.\n* Female participants must not donate, or retrieve for their own use, ova from the time of screening and throughout the study treatment period, and at least 90 days after the final study drug administration.\n* Has failed standard of care or refused next line therapy at the present time and if approved treatment options are still available, can delay approved treatments without harm as judged by the investigator (e.g., patients requesting a break between lines of therapy).\n\nAdditional Inclusion Criteria for Parts 2 and 3:\n\n* Measurable disease (as defined for Part 1) or recognised and abnormal biomarker levels (e.g., PSA for prostate cancer, CA15.3 for breast cancer).\n* Defined diseases or disease states of interest, suitable for dose expansion.\n* Patients who have enrolled in Part 1 of the study (dose-escalation), and in the opinion of the investigator, are benefitting from treatment, may be eligible for Parts 2 and 3.\n\nExclusion Criteria:\n\n* Participants who are unable to cease any anti-inflammatory medications or statins prior to and during the study, including non-steroidal anti-inflammatories, oral steroids at any dose; topical steroids and anti-inflammatories are allowable.\n* Participants who have participated in other clinical trials and received investigational products within 4 weeks, or within five half-lives of the treatment, whichever is longer, before Cycle 1 Day 1 of the study period.\n* Previous adverse reactions which have not returned to Grade 0 or 1 according to NCI-CTCAE v5.0 (except alopecia and fatigue) at the screening visit.\n* A clinically significant active infection determined by the investigator.\n* Significant or recurrent third space accumulation (e.g., ascites or pleural effusions) according to the investigator.\n* Has a medical history of myocardial infraction or unstable angina within 6 months before enrolment.\n* Has a medical history of symptomatic CHF (New York Heart Association (NYHA) classes II-IV) or serious cardiac arrhythmia requiring treatment.\n* Has a history or presence of uncontrolled mental illness.\n* The participant is expected to be non-compliant with critical trial procedures and is not willing or able to adhere to the trial requirements during the study.\n* Participants are deemed inappropriate for this clinical trial at the discretion of the investigator.\n\nAdditional Exclusion Criteria for Parts 2 and 3:\n\n\\- Patients must not have more than 2 prior lines of therapy.",{"count":90,"type":20},80,[92,68],"PHASE1","This clinical trial is an adaptive study of a novel vimentin inhibitor in cancers.\n\nIt is an open label, multicentre, single ascending dose level in phase I and cohort exploration in phase II.\n\nPrimary objective is to evaluate safety and tolerability of KESONOTIDE™ as a monotherapy in participants with advanced\u002Fmetastatic solid cancers.\n\nSecondary objective is to characterise the pharmacokinetics of KESONOTIDE™. Phase I study will enrol 20-32 participants and Phase II approximately 80 participants.",[24,25,95,96,97,98,99],"Lung Cancers","Ovarian Cancer","Glioblastoma Multiforme (GBM)","Pancreas Cancer","Skin Cancer",[101],"kesonotide, vimentin inhibotor","2026-03-15",{"date":104,"type":37},"2026-03-17",{"date":106,"type":37},"2025-11-07",{"date":108,"type":20},"2027-10-26",{"name":110,"class":44},"Filamon LTD",3,{"id":113,"slug":4,"hasResults":10,"nctId":114,"briefTitle":115,"officialTitle":115,"acronym":116,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":123,"conditions":124,"keywords":131,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100571211","NCT06717295","The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling","CCANED-CIPHER","Phase 1 (Common Cancer Early Detection - CCANED)\n\nInclusion Criteria:\n\n* Age: Adults aged 40 years or older.\n* Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer.\n\nExclusion Criteria:\n\n* Currently pregnant.\n* Presence of any active infectious diseases.\n* Use of anticoagulant or antiplatelet drugs within the past 2 weeks.\n* Any medical or psychological conditions that may affect the participant's ability to comply with study procedures.\n\nPhase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER)\n\nInclusion Criteria:\n\n* Adults aged 40 years or older.\n* Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC)\n* Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).\n\nExclusion Criteria:\n\n* Presence of another malignancy unless it has been in remission for at least 5 years.\n* Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes.",true,"40 Years","75 Years",{"count":122,"type":20},6000,"The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.",[125,126,127,24,96,128,129,130],"Brest Cancer","Lung Cancer (NSCLC)","Pancreatic Cancer, Adult","Colorectal Cancer","Glioblastoma (GBM)","Liver Carcinoma",[132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,27],"cancer screening","Liquid Biopsy","AI-based Diagnostics","Early Cancer Detection","Circulating Tumor DNA (ctDNA)","RNA Profiling","Biomarker","Precision Medicine","Oncology","Health Data Analysis","Platelets","treatment response","RNA","CircRNA","Splicing","2025-12-29",{"date":149,"type":37},"2026-01-02",{"date":151,"type":37},"2025-12-20",{"date":153,"type":20},"2028-08-01",{"name":155,"class":44},"Javier Toledo",4,{"id":158,"slug":4,"hasResults":10,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":163,"targetDuration":4,"studyType":66,"phases":165,"briefSummary":167,"conditions":168,"keywords":171,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100589890","NCT06960291","Sustainable Implementation of the EXCEL Exercise Oncology Program Across Canada","EXCEL","Inclusion Criteria:\n\n* have or had a diagnosis of cancer;\n* be 18 years or older;\n* be able to participate in low-intensity levels of activity, at minimum;\n* be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), have received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, have a referral from their healthcare team indicating they have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise;\n* be able to provide informed written consent in English or French\n\nExclusion Criteria:\n\n* does not or did not have a cancer diagnosis\n* is under the age of 18\n* is unable to participate in mild exercise, at minimum\n* is not pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), has not received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, doesn't have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise\n* unable to read\u002Fwrite in English\n* for online programs, does not have internet or computer access",{"count":164,"type":20},740,[166],"NA","EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-trained exercise specialists in Canada, outside of the research setting. Considering the negative impact cancer and its treatments have on fitness and physical activity levels, community-based efforts towards improving access, uptake and maintenance of exercise programming are needed.\n\nThis study will evaluate the benefits of a community-based or online EXCEL exercise program for people living with and beyond cancer across Canada, using a streamlined intake process compared to the original EXCEL Study (HREBA.CC-20-0098, NCT04478851). This 8 to 12-week program (intervention) will be delivered in-person or over virtual platform. It includes twice weekly supervised exercise classes.",[27,24,169,170,95],"Breast Cancers","Colon Cancer",[172,173,174,175,176,177,178,179],"Exercise oncology","Exercise","Physical activity","community program","online exercise","cancer survivor","individual living with and beyond cancer","quality of life","2025-10-02",{"date":182,"type":37},"2025-10-07",{"date":184,"type":37},"2025-03-11",{"date":186,"type":20},"2026-11-30",{"name":188,"class":81},"University of Calgary",5,{"id":191,"slug":4,"hasResults":10,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":195,"eligibilityCriteria":196,"healthyVolunteers":10,"sex":197,"minAge":17,"maxAge":4,"enrollmentInfo":198,"targetDuration":200,"studyType":21,"phases":4,"briefSummary":201,"conditions":202,"keywords":203,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":57},"100562793","NCT06607783","PRostate Cancer Enhanced Diagnosis by Calibration Technology","A Multi-Centre, Pivotal Stage, Study to Determine the Between MRI Scanner Reproducibility of Gold Standard Phantom Calibrated Acquisition Replicator (CARE) for Measurement of Apparent Diffusion Coefficients in the Prostate of Patients With MR Positive Lesions Destined for Biopsy","PREDICT","Inclusion Criteria:\n\n* Men aged 18 years and older undergoing investigations for PCa.\n* Standard of Care MRI conducted.\n* One or more lesions with a Likert score of 3 or above identified on clinical reports.\n* Planned targeted biopsy within 6 months from the date of clinical care MRI.\n* Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n* Prostate specific antigen (PSA) level \\> 20ng\u002Fml within 6 months\n* Previous diagnosis of prostate cancer\n* Ongoing hormone treatment within 3 months prior to MRI, excluding antiandrogens or 5-alpha reductase inhibitors\n* Contraindication to MRI scan","MALE",{"count":199,"type":20},66,"3 Months","The CARE® Phantom system is a medical device system that is being developed has been designed to enable the quantitative measurement of the apparent diffusion coefficient (ADC) in the prostate of patients undergoing a multi-parametric MRI (mpMRI) scan to detect prostate cancer. The final device system will comprise three elements: a calibration mat containing phantoms and embedded monitoring software, a docking station to transfer data from the phantoms, and software as a medical device (SaMD) for calibrating the resulting mpMRI images.\n\nIn this clinical trial, patients will undergo MRI scanning in different scanners using the GSP Phantoms to provide mpMRI images and phantom data for subsequent in silico analysis. The captured images and data will be used to further develop and calibrate the GSP prototype SaMD part of the medical device system, and to establish the degree of optimised reproducibility that can be achieved.",[24],[204,205,206,207,208,209,210,211,212,213,214,215],"MRI","Calibration","Prostate Cancer","Quantitative Imaging Biomarker","Reproducibility","Data interoperability","Phantom","Apparent Diffusion Coefficient","ADC","PIRAD","Diagnosis","Biopsy","NOT_YET_RECRUITING","2025-08-22",{"date":219,"type":37},"2025-08-28",{"date":221,"type":20},"2025-09",{"date":223,"type":20},"2026-12",{"name":225,"class":44},"Gold Standard Phantoms",{"id":227,"slug":4,"hasResults":10,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":232,"targetDuration":4,"studyType":66,"phases":234,"briefSummary":235,"conditions":236,"keywords":255,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":57},"100568639","NCT06683846","Ivonescimab in the Treatment of Multiple Advanced Tumors","Ivonescimab (PD-1\u002FVEGF Bispecpecial Antibody) in the Treatment of Multiple Advanced Tumors: a Multi-cohort, Multi-center, Single-arm Phase II Study","Inclusion Criteria:\n\n* Individuals able to understand and give written informed consent.\n* Histologically or cytologically confirmed cancer of one of the following types:\n\nPAGET's disease of scrotum with infiltrating sweat gland carcinoma Paraganglioma Pheochromocytom, Renal angiomyolipoma Malignant perivascular epithelioid cell tumor, Rhabdomyosarcom Other sarcoma rather than rhabdomyosarcom\n\n* Stage IV disease\n* Adequate performance status (ECOG 0-2)\n* Expected survival ≥ 3 months.\n* Measurable disease by CT or MRI, Or lesions with skin infiltration.\n* Adequate hematology without ongoing transfusional support (hemoglobin \\> 9 g\u002FdL, absolute neutrophil count (ANC) \\> 1,500 per mm\\^3, platelets \\> 100,000 per mm\\^3).\n* Adequate renal and hepatic function (creatinine ≤ 2.0 x institutional upper limit of normal (IULN), bilirubin ≤ 1.5 IULN, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x IULN or 5 x IULN if know liver metastases).\n* Adequate coagulation function: International Normalized Ratio (INR) ≤1.5 \u002FPT≤1.5×ULN, aPTT≤1.5×ULN.\n* Willing to use a medically approved contraceptive method from the enrollment to at least 120 days after the end of the study, and sperm donation to another person or cryopreservation for fertilization and reproduction is not permitted during this period.\n* Ability to comply with research visit schedules and other protocol requirements.\n\nExclusion Criteria:\n\n* With any severe and\u002For uncontrolled disease. Including: (1)Poor blood pressure control (systolic blood pressure ≥150mmHg or diastolic blood pressure ≥100mmHg); (2) poor control of diabetes (fasting blood sugar \\[FBG\\] \\>10mmol\u002FL);\n\n  ≥2 grade myocardial ischemia or myocardial infarction, arrhythmia (QTc≥470ms), and ≥2 grade congestive heart failure (NYHA classification); (3)active or uncontrolled severe infections requiring systemic antibacterial, antifungal, or antiviral treatment (≥CTCAE 2-level infection), including tuberculosis infection; A history of active tuberculosis; (4)Uncontrolled ascites, pleural effusion, or pericardial effusion that require repeated drainage;\n* With active hepatitis (transaminase levels not meeting inclusion criteria; HBV reference: HBV DNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; HCV reference: HCV RNA≥2000 IU\u002Fml or ≥10\\^4 copies\u002Fml; after nucleoside analog antiviral therapy below the above standard, can be included; chronic hepatitis B virus carrier, HBV DNA\\\u003C10\\^4 IU\u002Fml, must be treated with antiviral drugs during the trial period to be eligible for enrollment);\n* History of immunodeficiency, including HIV positive or subjects with other acquired or congenital immunodeficiency diseases;\n* Active autoimmune disease requiring systemic treatment within the past two years, or subjects with an autoimmune disease that the investigator judges may recur or is planned for treatment; except: non-systemic treatment of skin diseases (e.g. vitiligo, alopecia, psoriasis or eczema); autoimmune thyroiditis-induced hypothyroidism requiring stable dose replacement therapy with hormones; 13. Subjects who have experienced severe hypersensitivity reactions after using monoclonal antibodies; individuals who are known to be allergic to the active ingredients or excipients of the study drug;\n* Have participated or are currently participating in another clinical study within the past 4 weeks prior to study entry;\n* Received a live vaccine within the past 30 days prior to the first dose or plan to receive a live vaccine during the study;\n* History of severe allergies;\n* At risk of bleeding, or with impaired coagulation function, or currently receiving thrombolytic therapy;\n* History of substance abuse with an inability to abstain or a history of mental illness;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study, or who, in the opinion of the investigator, have other reasons not to be enrolled; Subjects who have a history of a clearly defined neurological or psychiatric disorder, such as dementia, epilepsy, or a history of seizure susceptibility;\n* Subjects who, in the opinion of the investigator, have a serious underlying condition that would endanger the subject's safety or impair the subject's ability to complete the study (such as severe diabetes, thyroid disorders, and mental illness), or who have a serious and\u002For unstable medical, psychological, or other condition (including laboratory abnormalities) that would affect the subject's safety or the subject's ability to provide informed consent, or who have any condition that would affect the study protocol and follow-up plan, including psychological, familial, social, or geographic factors;",{"count":233,"type":20},400,[68],"The goal of this clinical trial is to learn if Ivonescimab works to treat advanced rare tumors including cohort 1: PAGET's disease of scrotum with infiltrating sweat gland carcinoma. cohort 2: Metastatic paraganglioma and pheochromocytoma. cohort 3: Metastatic renal angiomyolipoma and malignant perivascular epithelioid cell tumor.\n\ncohort 4: Rhabdomyosarcoma and Ewing's sarcoma cohort 5: Collecting duct carcinoma cohort 6: Urachal carcinoma. cohort 7: Neuroendocrine cancer. cohort 8: Basal cell carcinoma and sarcomatoid carcinoma. cohort 9: Penile cancer. cohort 10: Adrenal cortical cancer. cohort 11: Metastatic germ cell tumors, failure of standard cisplatin based therapy (mostly testicular cancer).\n\ncohort 12: Non-clear cell renal carcinoma (including renal papillary renal carcinoma); Renal cancer cannot be classified).\n\ncohort 13: Non-clear cell renal carcinoma (including chromophobe renal carcinoma) cohort 14: Other rare tumors that cannot be classified (such as testicular reticulum adenocarcinoma, etc.).\n\ncohort 15: Prostate cancer. cohort 16: Clear cell renal carcinoma. (16.1: received PD-1; 16.2: no PD-1 received) cohort 17: Urothelial carcinoma. cohort 18: Kidney cancer with brain metastases. cohort 19: Brain metastases of urothelial carcinoma. cohort 20: Rare tumors with brain metastases.\n\nIt will also learn about the safety of Ivonescimab. The main questions it aims to answer are:\n\nDoes Ivonescimab improve the objective response rate and prolong the survival of participants? What medical problems do participants have when taking Ivonescimab?\n\nParticipants will:\n\nReceive Ivonescimab 20mg\u002Fkg intravenously every 21 days until disease progression, intolerable toxicity, or full 2 years of treatment, whichever occurs first.\n\nBe performed imaging evaluation according to RECIST 1.1 every 9 weeks for 1 year of treatment and every 12 weeks after 1 year Be recorded any adverse events in the whole study period including type, incidence, grade, severity, duration, and association with the study drug according to NCI-CTCAE V5.0 criteria",[237,238,239,240,241,242,243,244,245,246,247,248,249,250,24,251,252,253,254],"Pheochromocytoma\u002FParaganglioma","Rhabdomyosarcoma","Paget Disease, Extramammary","Renal Angiomyolipoma","Perivascular Epithelioid Cell Tumor, Malignant","Sarcoma","Urachal Cancer","Neuroendocrine Cancer","Basal Cell Carcinomas","Sarcomatoid Carcinoma","Penile Cancer","Adrenal Cortical Cancer","Germ Cell Cancer Metastatic","Non-Clear Cell Renal Cell Carcinoma","Clear Cell Renal Cancer","Urothelial Carcinoma","Kidney Cancer","Rare Tumors",[256,257,258],"rare tumor","Ivocizumab","immunotherapy","2025-08-19",{"date":261,"type":37},"2025-08-24",{"date":263,"type":37},"2024-11-20",{"date":265,"type":20},"2027-11-30",{"name":267,"class":81},"Fudan University",{"id":269,"slug":4,"hasResults":10,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":10,"sex":197,"minAge":17,"maxAge":4,"enrollmentInfo":274,"targetDuration":4,"studyType":66,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":281,"lastUpdatePostDateStruct":282,"startDateStruct":284,"completionDateStruct":286,"leadSponsor":288,"locationsCount":290},"100575737","NCT06776172","Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.","Extended Pelvic Lymph Node Dissection vs. No Pelvic Lymph Node Dissection at Radical Prostatectomy in PSMA PET Negative Staged Men: A Multicenter, Randomized Phase III Trial","Inclusion Criteria:\n\n* Age ≥ 18 years and life expectancy \\>15 years\n* Any biopsy-proven WHO\u002FISUP grade groups III-V PCa\n* High-risk prostate cancer defined as:\n\n  * Any biopsy-proven WHO\u002FISUP grade group III-V PCa or\n  * ISUP grade group II and PSA \\> 20 ng\u002Fml\n* PSMA-PET: negative staging for regional and distant metastasis\n* multidisciplinary tumorboard recommendation for radical prostatectomy\n* WHO performance status 0-1\n* Adequate condition (ASA ≤ III) for general anesthesia and RP\n\nExclusion Criteria:\n\n* ISUP grade group I PCa and cT1 or cT2 (MRI)\n* cT4 (MRI) PCa\n* PSMA-PET: positive staging for local and distant metastasis\n* Any prior neoadjuvant, local or systemic treatment for PCa\n* Previous PLND or pelvic radiotherapy\n* Patients with a prior malignancy and treated with curative intention are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and\u002For no late recurrence.\n* Any other serious underlying medical, psychiatric, psychological, familial, or geographical\n* condition, which in the judgment of the investigator may interfere with the planned\n* staging, treatment and follow-up, which affect patient compliance or place the patient at\n* high risk from treatment-related complications.\n* Vulnerable men (participants incapable of judgment or participants under tutelage) will not be included in the study.",{"count":233,"type":20},[166],"The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.",[278,24],"Prostate Cancer Surgery",[280],"Pelvic Lymph Node Dissection","2025-06-30",{"date":283,"type":37},"2025-07-03",{"date":285,"type":37},"2025-02-10",{"date":287,"type":20},"2040-02",{"name":289,"class":81},"University Hospital, Basel, Switzerland",15,{"id":292,"slug":4,"hasResults":10,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":10,"sex":197,"minAge":17,"maxAge":120,"enrollmentInfo":297,"targetDuration":4,"studyType":66,"phases":299,"briefSummary":300,"conditions":301,"keywords":306,"overallStatus":216,"whyStopped":4,"lastUpdateSubmitDate":316,"lastUpdatePostDateStruct":317,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":57},"100586479","NCT06915909","Robotic Prostatectomy Artificial Intelligence Low Pressure Pain (RALP) Trial","Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial - \"The Monitoring of Patients Outcomes Intraoperatively and Perioperatively Using the Airseal and Stryker Insufflator Undergoing Robotic Assisted Laparoscopic Prostatectomy at a Pressure and Stability of Pneumoperitoneum of 8 mmHg\"","Inclusion Criteria:\n\n* Patient indicated for non-emergent robotic Prostatectomy surgery\n* Patients (or appropriate legal representatives) able to provide written informed consent to participate in the study\n* Males, aged 18 to 75 years\n* Have no significant psychopathology that could limit the subject's ability to understand the procedure, comply with medical, surgical, and\u002For behavioural recommendations and office visits\n* Are American Society of Anaesthesiologists (ASA) Class I, II, or III);\n\nExclusion Criteria:\n\n* Patient participation in a different investigational clinical study within 90 days before screening and for the duration of this trial (unless previously approved by the investigator and Sponsor);\n* Patients requiring any surgical procedure in addition to Prostatectomy and or \u002F Pelvic Lymph node dissection\n* Previous pelvic surgery or previous malabsobtion or restrictive procedures performed for the treatment of obesity\n* Inability to provide informed consent\n* Unable or unwilling to attend follow-up visits and examinations\n* Uncontrolled hypertension (=\u002F\\>Systolic: 180 mmHg\u002FDiastolic: 120 mmHg) and\u002For diabetes mellitus (Blood sugar level: \\>200 mg\u002FdL)\n* Patients who fall into American Society of Anesthesiologists (ASA) Class ≥ IV\n* History of chronic alcohol or drug abuse within 2 years of the screening visit\n* Chronic renal failure or on dialysis\n* Significant complicating medical history or immunocompromised\n* History or presence of pre-existing autoimmune connective tissue disease, e.g., systemic lupus erythematosus or scleroderma\n* Immunocompromised such as that resulting from chronic oral steroid use, chemotherapeutic agents, or immune deficiency disorders;\n* Any medical condition which precludes compliance with the study\n* Subjects with any other clinically significant unstable medical disorder, life threatening disease, or conditions that, in the opinion of the investigator, may jeopardize the subject's well-being and\u002For the soundness of this clinical study or which would contra-indicate a surgical procedure.\n* Previous or current history of being on regular analgesia \u002F pain killers",{"count":298,"type":20},40,[166],"The 'Robotic Prostatectomy Artificial Intelligence Low Pressure Pain Study Trial' aims to assess the feasibility of being able to review operative outcomes such as pain when comparing two commonly used surgical devices for the removal of prostate cancers. The data collected will inform methodologies for future, larger, multi-center trials investigating pain in patients undergoing prostate cancer surgery.\n\nA robotic prostatectomy is a commonly performed surgery used to treat prostate cancer by removing the prostate gland. In order to perform the procedure, the surgeon must 'inflate' (technical term pneumoperitoneum) the patients abdomen with carbon dioxide gas using a device called an insufflator. Adequate 'inflation' of the abdomen ensures the surgeon can clearly visualise the prostate. Unfortunately, higher pressures of abdominal 'inflation' are a large contributor to intra and post-operative pain in patients having prostatectomies. The type of insufflator device used to maintain inflation pressures in the abdomen are thought to be a variable contributing to differing levels of intra and post-operative pain. Therefore, the purpose of this trial is to compare intra and post-operative pain when using two different insufflator devices when performing robotic prostatectomies. Both insufflators are already commonly used across multiple NHS Trusts.\n\n40 patients awaiting a robotic prostatectomy at the urology department at the Lister hospital, Stevenage, will be randomised to use either the Conventional Insufflator System (CIS) {Stryker PneumoClear Insufflator} or the AIRSEAL® Insufflation System (AIS) to 'inflate' their abdomens during their prostatectomies. Data relating to various intra and post-operative outcomes will be collected in the 30 days following the patient's operation. Outcomes include levels of intra and post-operative pain, medication use, procedure time, recovery room time, length of hospital stay, post operative nausea and vomiting and adverse events. This data can be analysed to identify trends in differences in outcomes between the AIS and CIS insufflators.",[302,303,278,24,304,305],"Prostate Cancer (Adenocarcinoma)","Prostate Cancer (Post Prostatectomy)","Prostate Neoplasm","Prostatectomy",[307,308,309,310,311,312,313,314,315],"prostate cancer","prostatectomy","robotic prostatectomy","post-operative pain","pain","Stryker PneumoClear insufflator","AirSeal Insufflation System","intra-operative pain","Medasense","2025-03-31",{"date":318,"type":37},"2025-04-08",{"date":320,"type":20},"2025-04-01",{"date":322,"type":20},"2025-07-01",{"name":324,"class":325},"East and North Hertfordshire NHS Trust","OTHER_GOV",{"id":327,"slug":4,"hasResults":10,"nctId":328,"briefTitle":329,"officialTitle":330,"acronym":331,"eligibilityCriteria":332,"healthyVolunteers":118,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":333,"targetDuration":4,"studyType":66,"phases":335,"briefSummary":336,"conditions":337,"keywords":346,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":352,"lastUpdatePostDateStruct":353,"startDateStruct":355,"completionDateStruct":357,"leadSponsor":359,"locationsCount":361},"100466092","NCT05349227","Comprehensive Outcomes for After Cancer Health","Comprehensive Outcomes for After Cancer Health (COACH): the Feasibility and Impact of an MHealth Augmented Coaching Program for Self-Management in Cancer Survivors","COACH","Inclusion Criteria:\n\n1. Have primary diagnosis of cancer;\n2. Are within 1 year of completion of primary therapy OR have a diagnosis of metastatic cancer\n\n   1. For the purpose of this study, primary therapy is defined as treatment of curative intent, first-line or later, from which the individual is advancing to active surveillance or follow-up with or without maintenance therapy\n   2. For individuals with metastatic cancer, individuals may be included provided they completed primary therapy for a de novo diagnosis of metastatic disease within the last year, are within one year of completion of initial therapy for their primary cancer diagnosis for which disease progression has occurred, or who are within one year of receiving treatment for metastatic disease (including individuals currently receiving treatment).\n3. Are aged 18 years and older;\n4. Can read and consent to participate in the trial;\n5. Can read and speak English;\n6. Can complete study follow-up at pre-specified intervals;\n7. Have access to mobile technology (e.g. a smart phone or tablet) that would allow engagement in digital health coaching for the collection of PROs and wearable data.\n\nExclusion Criteria:\n\n1. Have a cognitive impairment (as assessed by their provider) that would prohibit the individual from engaging with the digital health coaching program or complete study assessments;\n2. Have a neurologic, musculoskeletal, or other comorbid condition that would impede their ability to engage in physical activity (as assessed by their provider)\n3. Have a life expectancy of \\<6 months, and\u002For\n4. Are on active treatment for relapsed disease. a. Individuals with disease progression or relapse which occurs following their consent to participate will be given the option to continue on study if they wish to do so. Data from individuals experiencing disease progression or relapse will be grouped for sub-analysis to explore if and how relapse impacts study outcomes.\n\nHealthy Volunteers must:\n\n1. Be adults aged 18 years or older or the age of majority in their state of residence, whichever is older.\n2. Must reside in the same dwelling as the patient participant\n3. Can read and consent to participate in the trial;\n4. Can read and speak English;\n5. Can complete study follow-up at pre-specified intervals;",{"count":334,"type":20},625,[166],"This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to participate in a randomized wait-list control study. Those in the intervention group will receive 6 months of digital coaching up front followed by 6 months of ongoing monitoring via patient reported and clinical outcomes, as well as wearable data. Those in the control group will be monitored via patient reported and clinical outcomes as well as wearable data for the first 6 months followed by 6 months of digital health coaching. Both groups will collect fecal microbiome samples at enrollment and month 6. The study aims to explore if and how digital health coaching may be used to enhance outcomes for individuals following completion of primary cancer therapy.",[96,25,338,339,340,341,342,24,343,344,345],"Lung Cancer","Gastric Cancer","Survivorship","Endometrial Cancer","Head and Neck Cancers","Geriatric Oncology","Metastatic Breast Cancer","Metastatic Cancer",[347,348,349,350,351],"Patient Reported Outcome Measures","Physical Activity","Digital Coaching","Microbiome","Wearables","2024-12-06",{"date":354,"type":37},"2024-12-11",{"date":356,"type":37},"2022-06-23",{"date":358,"type":20},"2027-05",{"name":360,"class":44},"Pack Health",7,{"id":363,"slug":4,"hasResults":10,"nctId":364,"briefTitle":365,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":10,"sex":197,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":66,"phases":370,"briefSummary":371,"conditions":372,"keywords":376,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":380,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":387,"locationsCount":111},"100565015","NCT06636682","FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer","A Multicenter, Adaptive, Phase 2, Randomized, Open-label Study of Irradiated Autologous Cellular Vaccine in Men With High-Risk Prostate Cancer Following Prostatectomy","Inclusion Criteria:\n\n* Has localized high-risk or very high-risk prostate cancer based on the NCCN v4.2023 classification.\n* Has ≥3 prostate biopsy cores with ≥50% tumor involvement.\n* Has PSA \\>4 ng\u002FmL ≤28 days prior to enrollment.\n* Has no evidence of distant metastases based on PSMA-PET\u002FCT performed ≤28 days prior to enrollment.\n* Is a candidate for radical prostatectomy, and scheduled radical prostatectomy date must be 3 to 14 days after enrollment.\n* Has not received nor plans to receive neoadjuvant (preoperative) radiation therapy, androgen deprivation therapy (ADT), or any other anticancer therapy.\n* Has a life expectancy \\>5 years.\n\nAdditional key eligibility criteria immediately postoperative for inclusion in the randomized population include:\n\n* Stage \\>pT3a (tumor has extended outside of the prostate on one side).\n* Gleason score of 8, 9, or 10 (high\u002Fvery high) on prostatectomy specimen.\n* Subjects with pT3b or pT4 tumors with a Gleason sum 7 (4+3) are eligible.\n* Pelvic lymph node dissection (PLND) is required with either pN0 or pN1 nodal staging permitted.\n* Subjects must have negative surgical margins or microscopic-only positive surgical margins.\n\nFinal eligibility criteria at 2 months postoperative for randomization include:\n\n* FK-PC101 has been produced for the subject and meets all release specifications.\n* An undetectable PSA (\\\u003C0.04 ng\u002FmL) on the most recent test performed prior to randomization (Day -4 to -7).\n* No prior, current, or planned future postoperative or adjuvant XRT, hormonal therapy such as ADT, or any other anticancer therapy (future therapy should not be administered until evidence exists of prostate cancer disease recurrence \\[such as PSA recurrence\\]).\n* Adequate organ function based on CBC and chemistry studies within 2 weeks of Day 1 (Day -14 to -7). Specific laboratory requirements include:\n\n  * Absolute neutrophil count (ANC) \\>1000\u002FµL\n  * Platelet count \\>100,000\u002FµL.\n  * Hemoglobin \\>8.0 gm\u002FdL.\n  * Estimated glomerular filtration rate (eGFR) \\>60 mL\u002Fminute based on Cockcroft-Gault formula.\n  * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both \\\u003C2 × upper limit of normal (ULN).\n  * Albumin \\>3.0 gm\u002FdL.\n* Capable of giving signed informed consent, which includes compliance with the requirements and restrictions of the study.\n\nExclusion Criteria:\n\n* Has an additional active malignancy that may confound the assessment of the study endpoints. If the subject has a past cancer history (active malignancy within 2 years prior to study entry) with substantial potential for recurrence, this must be discussed with the Sponsor before study entry. Note: Subjects with the following concomitant neoplastic diagnoses are eligible: non-melanoma skin cancer and carcinomas in situ (including breast DCIS, transitional cell carcinoma\u002FNMIBC, anal carcinoma, and melanoma in situ).\n* Is eligible for and elects to receive adjuvant therapy following RP.\n* Has clinically significant cardiovascular disease (e.g., uncontrolled or any New York Heart Association \\[NYHA\\] Class 3 or 4 congestive heart failure, uncontrolled angina, history of myocardial infarction, unstable angina, pulmonary embolism or stroke within 6 months prior to study entry, uncontrolled hypertension, or clinically significant arrhythmias not controlled by medication).\n* Has uncontrolled, clinically significant pulmonary disease (e.g., chronic obstructive pulmonary disease, pulmonary hypertension) that in the opinion of the Investigator would put the subject at significant risk for pulmonary complications during the study.\n* Has known metastases, such as bone, visceral, or brain or leptomeningeal metastases.\n* Has an active autoimmune disease or Grade ≥3 pneumonitis that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) or treatment with drugs (e.g., neomercazol, carbamazole) that function to decrease the generation of thyroid hormone by a hyperfunctioning thyroid gland (e.g., in Graves' disease) is not considered a form of systemic treatment of an autoimmune disease.\n* Is currently receiving systemic steroid therapy at a prednisone equivalent dose of \\>10 mg daily for at least 1 week or other form of immunosuppressive therapy within 7 days prior to enrollment.\n* Has uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, disseminated intravascular coagulation, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n* Is at risk for disseminated BCG infection or has previously demonstrated an allergic response to BCG or its components.\n* Has known positive status for human immunodeficiency virus (HIV) or active or chronic Hepatitis (Hep) B or Hep C. Screening is not required.\n* Has any medical condition which in the opinion of the Investigator places the subject at an unacceptably high risk for toxicity.",{"count":369,"type":20},100,[68],"The goal of this clinical trial is to learn if the vaccine FK-PC101 works to delay or prevent the return of prostate cancer in men who have had surgery to remove their prostate cancer. It will also learn about the safety of FK-PC101. The main questions it aims to answer are:\n\nDoes FK-PC101 delay or prevent the return of prostate cancer following surgery? What medical problems do participants (subjects) have when taking FK-PC101?\n\nResearchers will compare FK-PC101 to current treatment practice to see if FK-PC101 works to prevent or delay the return of prostate cancer following surgery to remove the prostate cancer tumor.\n\nSubjects will:\n\nHave a sample of the prostate cancer tissue collected at the time of surgery to remove this tissue from the body. This tissue will then be used to create a personalized vaccine that is specific to your prostate cancer.\n\nIf randomly selected to receive the vaccine, subjects will receive the vaccine up to 7 times over a 6-month period.\n\nIn addition to the treatment visits for those randomized to receive FK-PC101, there will be up to 4 follow up visits to the clinic over a 22-month (nearly 2 year) period.\n\nFor subjects randomized to receive current treatment practice, they will be asked to attend up to 8 visits over 22 months to track if there is any detectable cancer. Should their prostate cancer return within a year following surgery, they will be eligible to receive FK-PC101, which already had been produced and thus no additional tumor tissue would need to be obtained.\n\nSubjects in both study arms will have regular blood tests and scans to test whether their prostate cancer has returned.",[302,373,24,303,206,374,375],"Prostate CA","Prostate Cancer Patients Undergoing Radical Prostatectomy","High-risk Prostate Cancer",[377,305,378,379],"Vaccine","Autologous","Radical Prostatectomy","2024-10-17",{"date":382,"type":37},"2024-10-21",{"date":384,"type":37},"2024-10-14",{"date":386,"type":20},"2027-05-04",{"name":388,"class":44},"Cellvax Therapeutics Inc",""]